HE prognosis of patients with malignant brain tumor has not improved much over the last few years, despite treatments such as surgery, radiation therapy, and chemotherapy. Therefore, the development of novel therapies for malignant brain tumor is essential. The CNS is immunologically privileged, lacking lymphoid reactivity and normal immune surveillance. Recently, several groups have reported that immunotherapy protocols with intradermal vaccines of genetically modified tumor cells are effective in rodent brain tumor models. 12, 30 Dendritic cells are rare, hematopoietically derived leukocytes that form a cellular network involved in immune surveillance, antigen capture, and antigen presentation, 31 although the tumor cells themselves are poor APCs. It has now become clear that DCs may play an important supportive role in promoting and maintaining antigen-specific T cells in vivo. The DCs are also potent stimulators of naive T cells, and this function results from their expression of important costimulatory molecules, their residence in both lymphoid and nonlymphoid tissues, their ability to migrate from sites of antigen entry to lymphoid organs, and their efficient antigen processing and presentation of a wide variety of antigens. Immunization in which DCs loaded with tumor antigens are used represents a powerful method of inducing antitumor immunity. Data from recent studies have shown that immunizing mice with DCs pulsed with specific antigens can prime a CTL response that is tumor-specific and offers protective tumor immunity in the treated mice. 8, 27 Many strategies for delivering antigens into DCs have been established in murine models and are now undergoing evaluation in clinical trials. These strategies include the use of synthetic peptides when the tumor antigen is known, 8, 20, 27 stripped peptides from Class I molecules in murine tumors, 40 tumor RNA, 5 or tumor lysates. 4 The advantages of vaccinating with completely tumor-derived material are that the identity of the tumor antigens need not be known and that the presence of multiple tumor antigens reduces the risk of antigen-negative escape mutants. It is now clear that tumors of diverse histological origins and causes are susceptible to DC-based therapies.
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Dendritic cells are rare, hematopoietically derived leukocytes that form a cellular network involved in immune surveillance, antigen capture, and antigen presentation, 31 although the tumor cells themselves are poor APCs. It has now become clear that DCs may play an important supportive role in promoting and maintaining antigen-specific T cells in vivo. The DCs are also potent stimulators of naive T cells, and this function results from their expression of important costimulatory molecules, their residence in both lymphoid and nonlymphoid tissues, their ability to migrate from sites of antigen entry to lymphoid organs, and their efficient antigen processing and presentation of a wide variety of antigens. Immunization in which DCs loaded with tumor antigens are used represents a powerful method of inducing antitumor immunity. Data from recent studies have shown that immunizing mice with DCs pulsed with specific antigens can prime a CTL response that is tumor-specific and offers protective tumor immunity in the treated mice. 8, 27 Many strategies for delivering antigens into DCs have been established in murine models and are now undergoing evaluation in clinical trials. These strategies include the use of synthetic peptides when the tumor antigen is known, 8, 20, 27 stripped peptides from Class I molecules in murine tumors, 40 tumor RNA, 5 or tumor lysates. 4 The advantages of vaccinating with completely tumor-derived material are that the identity of the tumor antigens need not be known and that the presence of multiple tumor antigens reduces the risk of antigen-negative escape mutants. It is now clear that tumors of diverse histological origins and causes are susceptible to DC-based therapies.
Interleukin-12 is a heterodimeric protein consisting of two subunits (p35 and p40) and is secreted by APCs such as DCs and macrophages. 13 It also enhances the proliferation and cytolytic functions of T cells and NK cells and promotes these effector cells to produce a number of other cytokines, including IFN␥. 7 Furthermore, IL-12 directs the differentiation of uncommitted T cells toward the T helper Type 1, 16 which is critical for cell-mediated antitumor immunity. The antitumor effects of IL-12 are mediated by the activation of CTLs as well as NK cells 9 and by the induction of IFN␥ production by T cells and NK cells. 22 Recently, several investigators have reported potent antitumor effects of IL-12 delivery by using IL-12 gene-modified tumor cells or systemic administration of IL-12 protein. 7, 22, 33 Based on these results, clinical trials of IL-12 gene therapy have been completed using autologous fibroblasts. 17 A partial response was observed in patients with several types of cancer. Delivering activated DCs to the sites of tumor antigens genetically modified to express gene products that enhance their ability to elicit a response may bypass the requirement for selective recruitment and local activation, which are disordered within the tumor microenvironment. We have observed that IL-12 production in DCs is suppressed in patients with malignant brain tumor (unpublished data); therefore we suspect that one of the mechanisms of immunosuppressive properties in patients harboring these tumors is DC dysfunction, resulting in a failure to promote and maintain antigen-specific T cells. In an attempt to further enhance the immune response, we evaluated DCs transduced with IL-12 genes in a brain tumor model in mice and investigated whether IL-12 gene transduction in DCs might serve as a strategy in the treatment of malignant brain tumor.
Viral vectors commonly used for therapeutic DNA delivery include replication-deficient forms of adenovirus or retrovirus. Although retroviruses have the advantage of mediating stable gene transfer with a low potential for immunogenicity, this vector delivery system has some problems with respect to its therapeutic use including a difficulty in producing high titers of retrovirus, the fact that only actively dividing cells can be infected, and the possibility of insertional mutagenesis. 21 The adenovirus vector system, although capable of delivering genes with high efficiency to a wide spectrum of nondividing cells in vivo, 11 has promoted only transient expression with different gene products. Transient expression may result from a strong immune response of host cells against the adenovirus.
11 Semliki Forest virus, a member of the Alphavirus genus, has received considerable attention for use as a virus-based expression vector. The SFV expression system differs from currently available viral delivery systems in that it is an RNA virus known to generate high levels of protein expression in vitro. In addition, the SFV is less pathogenic 26 to humans. Semliki Forest virus is a self-amplifying expression vector that produces high-titered stocks of infectious particles, infects nondividing cells, and generates high-level expression of transgenes. 32 Nishioka, et al., 24 have shown that DCs injected intratumorally are capable of capturing tumor antigens in situ at the tumor site, migrating to regional lymph nodes, and inducing a subsequent systemic immune response against the tumor. Furthermore, these authors have demonstrated that intratumoral injection with IL-12 gene-modified DCs can suppress the growth of established tumors and induce an antitumor T-cell response. We have reported that genetically modified DCs pulsed with SFV-mediated tumor cDNA markedly enhances antitumor immune responses in murine glioma models, 37 and that induction of a therapeutic antitumor immunological response by intratumoral injection of genetically modified SFV produces IL-12. 38 In the study presented here we evaluated the efficacy of genetically modified DCs pulsed with SFV-mediated IL-12. The vaccines were studied in a model of active immunotherapy for CNS tumors.
Materials and Methods

Tumor Cell Lines and Animal Models
The B16 and 203 glioma cell lines were derived from C57BL/6 mice. We also used BHK cells. These cell lines were grown in minimal essential medium containing 10% fetal calf serum. Note that all cell lines were free from mycoplasma contamination. In all experiments we used 6-to 12-week-old female C57BL/6 mice, which were maintained in a virus-free environment and handled in accordance with the National Institutes of Health Laboratory Animal Resources Commission standards.
Generation of DCs From Bone Marrow Cultures
The procedure used in these studies was similar to that previously described. 4, 37 In brief, bone marrow was flushed from the femoral bones and depleted of red blood cells with ammonium chloride. Bone marrow cells were depleted of lymphocytes, granulocytes, and Ia cells by using a mixture of mAbs and complement. The mAbs used were 2.43 (CD8), GK1.5 (CD4), RA3-3A1/6.1 (CD45R), B21-2 anti-Ia (Tumor Immunology Bank Nos. 210, 207, 146, and 229, respectively), and RB6-8C5 anti-Gr-1. Cells were plated in six-well culture plates (10 6 cells/ml, 3 ml/well) in RPMI 1640 medium supplemented with 5% heat-inactivated fetal calf serum, 50 mM 2-mercaptoethanol, 10 mM HEPES (pH 7.4), 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 3.3 ng/ml granulocyte-macrophage colony-stimulating factor, and 1000 IU/ml IL-4. On Day 3 of culture, floating cells were gently removed. On Day 7 of culture, nonadherent cells and loosely adherent proliferating DC aggregates were collected, replated, and removed for analysis and immunizations. The quality of DC preparation was characterized by cell surface markers and morphological analysis. ) and appropriate isotype controls were used, and cytometric analysis was performed using a cell sorter.
Generation of SFV-IL-12 Particles
The plasmid pSFV3, pSFV3-LacZ, contains an SP6 promoter, a 7-kb fragment encoding the SFV RNA replicase, and a subgenomic promoter that is bound by the RNA replicase to synthesize large quantities of subgenomic RNA. A helper plasmid pSFV-Helper 2, which contains the genes for the structural proteins (capsid, E3, E2, 6K, and E1) required for packaging the viral genome, was used for construction of the recombinant envelope gene. Retrovirus vector DFG-IL-12 was kindly provided by Dr. Nishioka. 38 The IL-12 gene was amplified using DFG-IL-12 as a template and put into pSFV. The pSFV-EGFP was constructed by replacing the LacZ fragment in pSFV-LacZ with the EGFP fragment from the plasmid pEGFP-C1. The SFV-IL-12 RNA were transcribed in vitro and capped using SP6 RNA polymerase and capping analog. The BHK cells were transfected with SFV-IL-12 and pSFV-Helper 2 RNA, respectively, by electroporation. After 24 hours of transfection, culture supernatants were harvested and aliquots were stored at Ϫ80˚C. A retrovirus vector GCsap-IL-12 was generated. 36 Retroviral particles were also generated, as described elsewhere. 24 Infectivity of recombinant viruses to BHK cells and DCs was determined by transfer of the SFV and retroviral particles that can transduce the ␤-galactosidase gene, as previously described.
36-38
In Vitro Cytotoxicity Assay
In vitro cell-mediated cytotoxicity assays were performed using R. Yamanaka, et al.
standard procedures, as previously described. 35, 37 In this study, splenocytes obtained from immunized animals and controls were restimulated in vitro for 5 days on monolayers of mitomycin C-treated B16 cells. Target cells included B16 and 203 glioma cells.
Interferon-␥ and IL-12 Assays
Erythrocyte-depleted splenocytes (2 ϫ 10 6 cells/ml) were cultured for 48 hours in vitro with 2 ϫ 10 5 irradiated (30 Gy) B16 cells in 24-well culture plates. After 48 hours, culture supernatants were collected for measurement of murine IFN␥ release by performing standard ELISA. For the IL-12 assay, DCs were transduced with PBS, GCsap-IL-12, SFV-LacZ, and SFV-IL-12, respectively. After transduction, supernatant in DC culture was collected for 3 days and tested in an IL-12 ELISA.
Implantation of Brain Tumors
The B16 cells were harvested by trypsinization and washed twice in Dulbecco's PBS. The cells (500 cells in a volume of 5 l) were then implanted into the right caudate nucleus of the brains of C57BL/ 6 mice by performing stereotactic injection, as previously described. 39 The treated animals were examined macro-and microscopically. Intratumor cells were evaluated using anti-CD4 (L3T4), anti-CD8 antibody (Ly-2) and biotinylated anti-rat IgG by performing the avidin-biotin complex method.
In Vivo Depletion Test
We performed in vivo depletion of CD4 or CD8 T-lymphocyte subsets. We used the mAbs GK1.5 and 2.43 to deplete CD4 or CD8 T cells, and rat IgG antibody as a control. These were prepared from hybridoma culture medium by using affinity chromatography with protein G sepharose. We administered intraperitoneal injections of 1 mg of antibody in the mice three times on Days 1, 2, and 3. The efficacy of depletion was analyzed using an FACS and was determined to be 98 to 100% effective (data not shown). Five hundred viable B16 cells were implanted in the brains of naive mice, and these mice were treated starting 7 days later. Animals received treatments of three intratumoral injections spaced 1 week apart containing DCs pulsed with PBS or SFV-IL-12. On Day 14 after tumor injection, splenocytes were prepared for analysis of IFN␥ production by using ELISA.
Cell Death and Uptake Analysis
The cell death and uptake analysis was performed as described elsewhere. 37, 39 Briefly, the self-replicating SFV was transcribed in vitro from the pSFV-EGFP plasmid and then transfected into DCs. As a control, the plasmid pEGFP-C1 was also transfected into DCs. The green fluorescent protein-positive (green) and -negative cells were sorted and plated into 48-well plates (500 cells/well, 10 wells/group) and then viable cells were counted every 24 hours. In uptake experiments, DCs were transfected with SFV-IL-12 and then labeled 24 hours later with PKH26-GL. Labeled cells (10 6 ) were cocultured with 10 6 bone marrow-derived immature DCs prepared by culture of bone marrow cells for 4 days. Cells were then stained with FITClabeled anti-I-A b mAb and analyzed using an FACS.
Statistical Analysis
Survival estimates and median survival times were determined using the method of Kaplan and Meier. Survival data were compared using the Wilcoxon test. The Student t-test was used for calculating the significance of other data. Statistical significance was determined at probability levels of less than 0.05.
Sources of Supplies and Equipment
The B16 and 203 glioma cell lines were provided by Riken Cell Bank (Tsukuba, Japan). The BHK cells were obtained from Invitrogen (San Diego, CA). The minimal essential medium was purchased from Gibco-BRL (Gaithersburg, MD). The C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, ME).
The mAbs used to deplete bone marrow were obtained from the American Type Culture Collection (Rockville, MD), except for the 
Results
Generation of DCs and Infection With Recombinant Viruses
After 7 days of culture, DC aggregates were seen, and these cells were positive for MHC Class I, MHC Class II, CD11c, CD40, CD80, and CD86, as previously described. 37 Infectivities of recombinant viruses were determined by transfer of the pSFV-LacZ and GCsap-LacZ, which can transduce the ␤-galactosidase gene. Viruses had a very high infection titer against BHK cells (5 ϫ 10 7 LacZ cfu/ml) and DCs (2 ϫ 10 7 LacZ cfu/ml). The DCs could also be transduced with an SFV and a retroviral vector expressing LacZ genes with approximately 20 to 30% efficiency. After completing transduction procedures, the concentration of IL-12 p70 heterodimer released into the culture medium was measured using an ELISA. As shown in Fig. 1 12 from IL-12-transduced DCs ranged from 10 to 150 ng/ 10 6 cells per 72 hours for GCsap-IL-12 and 300 to 600 ng/ 10 6 cells per 72 hours for SFV-IL-12. Production of IL-12 protein by the gene-modified DCs was confirmed to be biologically active and capable of stimulating IFN␥ production from concanavalin A-treated splenocytes (data not shown).
Tumor-Specific Immune Response After Treatment With Intratumoral Injection of DCs Transduced by SFV-IL-12
We investigated whether intratumorally injected bone marrow-derived DCs pulsed with SFV-mediated IL-12 can induce tumor-specific CTLs. Standard cytotoxicity assays were performed using splenocytes harvested from immunized animals 3 weeks posttransplantation and restimulated for 5 days in vitro with irradiated target cells. Cytotoxic activity was tested against B16 (Fig. 2 upper) or 203 glioma (Fig. 2 lower) cells. As shown in Fig. 2 , immunization with DCs pulsed with SFV-mediated IL-12 induced B16-specific CTL responses that were statistically significant compared with responses in animals immunized with DCs pulsed with either SFV-LacZ or GCsap-IL-12 or DCs pulsed with PBS (p Ͻ 0.01).
Prolonged Survival of Mice Bearing CNS B16 Tumor and Immunized With DCs Pulsed With SFV-Mediated IL-12
In considering the clinical application of a tumor vaccination strategy, it is more realistic to treat animals in which tumors are present at the time of vaccination. Thus, 500 viable B16 cells (Fig. 3) were implanted in the brains of naive 
In Vivo Depletion Test
To identify the effector cells required for effective antitumor immunopotentiation by the tumor vaccine with SFV-IL-12, we performed in vivo depletions of lymphocyte subpopulations by administering antibodies in the treatment model. Intracranial tumor challenge with B16 cells was performed first and then we administered treatments three times with DCs pulsed with SFV-IL-12 in mice depleted of CD4 or CD8 T cells or rat IgG antibody as a control. Ninety days later, we estimated the duration of survival of the mice. Analysis revealed that the depletion of CD8 ϩ T lymphocytes completely abrogated the therapeutic effect of the tumor vaccine and that the depletion of CD4 ϩ T lymphocytes incompletely abrogated the therapeutic effect (Table 1) .
Dendritic Cells Transduced by SFV-IL-12 Stimulate IFN␥ Production by CD4
ϩ T Lymphocytes
Treatment with DCs pulsed with SFV-IL-12 can enhance the capacity to induce IFN␥ production. Mice harboring B16 tumor cells were treated as described. Spleen cells were harvested 14 days after tumor inoculation. For measurement of IFN␥ production, splenocytes from treated mice were stimulated in vitro. Culture supernatants were collected 48 hours later and evaluated for IFN␥ levels by using standard ELISA. As shown in Table 2 , splenocytes from mice immunized with DCs pulsed with SFV-IL-12 produced greater amounts of IFN␥ in response to relevant tumor compared with those immunized with DCs pulsed with PBS, SFV-LacZ, or GCsap-IL-12, respectively (p Ͻ 0.05). Furthermore, splenocytes from immunized mice were cultured for 48 hours in vitro with irradiated B16 cells in 24-well culture plates. After 48 hours, culture supernatants were collected for measurement of IFN␥ release by using standard ELISA. As shown in Table 3 , in vivo depletion of CD4 ϩ T cells abrogated IFN␥ production by the harvested splenocytes, demonstrating that IFN␥ production in vivo was dependent on CD4 ϩ T cells.
Evidence of Intratumoral Infiltration of CD8 ϩ T Cells in Mice Immunized With DCs Pulsed With SFVMediated IL-12
The brains of the animals immunized with DCs pulsed with SFV-IL-12 that survived past 90 days revealed no evidence of tumor, thus suggesting eradication of established lesions in these long-term survivors. Immunohistochemical analysis of mice immunized with DCs pulsed with SFV-IL-12 demonstrated an increased intratumoral infiltration of CD8 ϩ T cells (Fig. 4) at 30 days after tumor implantation. This suggests that the CTL response occurred in vivo. There was no significant effect such as demyelination or vascular compromise in normal brain area (data not shown).
Evidence of Apoptosis After Transfection With SFV and Uptake of SFV-Induced Apoptotic Cells by DCs
After being transfected with SFV-EGFP, cells rounded up, began to shrink, and stopped dividing after 24 hours. At 48 hours, these cells had nuclear fragmentation characteris- tic of apoptosis. Nearly all of the cells died by 96 hours. The proliferation of DCs transfected with a conventional DNA plasmid encoding EGFP remained similar to that of nontransfected control cells (Fig. 5 upper) . In uptake experiment, PKH (red) and I-A b (green) were evaluated at 3 and 24 hours using FACS analysis. Double-positive cells were counted as a fraction of total FACS events. The uptake of SFV-induced apoptotic cells by DCs is also evident (Fig. 5  lower) .
Discussion
In this study, we showed that use of a vaccine strategy prolonged survival of tumor-bearing animals, probably by induction of a CTL response. The treatment of tumor-bearing mice with DCs pulsed with SFV-IL-12 led to a dramatic reduction in the mortality rate at 90 days. At that time, 40% of the treated animals were still alive, and histological analysis indicated that SFV-IL-12 DC therapy led to the eradication of established tumors in the long-term survivors. Systemic immune responses, as demonstrated by CTL activity, were significantly higher and tumor specific when IL-12 transduced DCs were used. Depletion of either CD4 ϩ or CD8
ϩ T cells by antibody treatment abrogated the efficacy of SFV-IL-12 DC therapy, thus indicating that the host-derived mechanism of tumor regression mediated by DC immunizations involved both T-cell subsets. These findings suggest that SFV-IL-12 DC therapy could augment the function of CD4 ϩ T cells to produce a T helper Type 1 cytokine and IFN␥ and generate CD8 ϩ T cell activity.
Nine reports 1, 3, 4, 6, 15, 19, 23, 25, 37 about primary brain tumor models of DC-based therapy have been published. In these studies, researchers have used a variety of antigens such as tumor lysate or mRNA admixed liposome, whole or single tumor peptide, virus vector-mediated tumor cDNA or tumor antigen MART1, and fusions of DCs and tumor cells. Most investigators used bone marrow as a source of DCs, although one group used a cloned DC line. The chosen route of administration was usually intraperitoneal, but two subcutaneous and one intravenous paths were also used. We have attempted to develop effective immunotherapy protocols with gene-modified DCs. The novelty of our study lies in the use of SFV to express IL-12 on DCs.
Recent advances in tumor immunology have made it possible to evaluate new cytokine-based anticancer therapies. 10 Among the many cytokines evaluated as anticancer agents, IL-12 has conferred potent antitumor immunity in murine tumor models. 4, 22, 27, 33, 37 Systemic administration of IL-12 was associated with severe dose-dependent toxicity in patients during the first trial in humans, however. The localized transfer of cytokine genes may circumvent some of the toxicity of systemic IL-12 delivery and provide adequate local cytokine levels for immune cell activation. 22, 28, 34 In a recent report investigators demonstrated that IL-12 acts directly on DCs to promote nuclear localization of nuclear factor-kappa B and primes DCs for IL-12 production.
14 This explains why DCs transduced by IL-12 are more effective in tumor treatment applications. Intratumoral injection of DCs was used as an alternative approach, which does not require pulsing of DCs with tumor-derived materials. Cytokine and chemokine production induced by IL-12 stimulation at the tumor site might be responsible for these effects through the alteration of the tumor microenvironment. It also has been documented that a number of individual cytokine genes are effective in gene therapy studies in mouse tumor systems. 10 Intratumorally injected DCs that have been transiently transduced with IL-12 do not require pulsing of DCs with a source of tumor antigen to induce tumor regres- sion. This approach should be one of the new future directions pursued in DC-based glioma immunotherapy.
The SFV is being developed as a vector for the expression of heterologous genes and it has many advantages for expression vector systems. In previous studies we have reported on the usefulness of SFV in immunogene therapy for brain tumor. [36] [37] [38] In SFV systems, because helper RNA does not contain a packaging signal, it will not form a defective interfering particle or be packaged with recombinant RNA. Furthermore, replication occurs entirely in the cytoplasm of the infected cells as an RNA molecule, without a DNA intermediate. 32 This is in contrast with retroviruses, which must enter the nucleus and integrate into the host genome to initiate vector activity. Thus, retrovirus vectors have applications for long-term expression of foreign genes, whereas SFV vectors are useful primarily for transient high-level expression. Furthermore, although adenovirus vectors can express high levels of foreign genes, these systems are more complex than SFV and express many highly antigenic virus-specific gene products, including structural proteins. 29 In contrast, currently SFV expresses only the four viral replicase proteins (nsP1-4) required for RNA amplification in the transduced cells. The self-replicating RNA produced more than 200% of the amount of antigen produced by a conventional DNA immunogen. 39 This system has been found to express significant quantities of heterologous proteins in vitro 18 and in vivo. 26 As we have shown, DCs acquire antigen from other apoptotic cells (namely DCs) for further presentation to T cells. 2, 37, 39 Furthermore, SFV induces apoptosis in infected cells. 37 Thus, it is possible that both, activation and apoptosis, which are induced in DCs on SFV-IL-12 infection, play an important syngeneic role in the initiation of specific immune responses against tumor cells. The other mechanism underlying the enhanced immunogenicity is the enhanced uptake of antigen by DCs and other professional APCs that die apoptotically as a result of the replicase activity. Data from this study suggest that intratumorally injected nontransduced immature DCs can acquire and process tumor antigens in situ, migrate to lymphoid organs, and then initiate a significant tumor-specific immune response. In summary, we assert that intratumoral injection with IL-12 gene-modified DCs by SFV mediates an effective antitumor response that is both superior to that observed using nontransduced DCs and retroviral-transduced DCs and capable of inducing systemic antitumor immunity. Thus, a self-replicating SFV system could serve as a powerful tool in treating malignant brain tumor.
Conclusions
This protocol, in which DCs pulsed with SFV-mediated IL-12 were used to treat experimental brain tumor, showed prolongation of survival in tumor-bearing animals and induction of a CTL response. Thus, the self-replicating SFV system may open novel approaches for the treatment of malignant brain tumor.
